Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors.
Ai Q, Li F, Zou S, Zhang Z, Jin Y, Jiang L, Chen H, Deng X, Peng C, Mou N, Wen C, Shen B, Zhan Q.
Ai Q, et al. Among authors: mou n.
Front Immunol. 2023 May 23;14:1161538. doi: 10.3389/fimmu.2023.1161538. eCollection 2023.
Front Immunol. 2023.
PMID: 37287989
Free PMC article.